- Home
- ACRS vs ESQ Comparison
ACRS vs ESQ Comparison
Compare ACRS & ESQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACRS | ESQ |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.5M | 941.0M |
| IPO Year | 2015 | 2017 |
Fundamental Metrics
Financial Performance| Metric | ACRS | ESQ |
|---|---|---|
| Price | $6.16 | $114.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $10.20 | ★ $120.33 |
| AVG Volume (30 Days) | ★ 1.9M | 117.1K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 0.76% |
| EPS Growth | ★ 69.01 | 14.20 |
| EPS | N/A | ★ 2.89 |
| Revenue | ★ $1,683,000.00 | N/A |
| Revenue This Year | N/A | $35.15 |
| Revenue Next Year | $4.24 | $39.09 |
| P/E Ratio | ★ N/A | $38.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.74 | $92.33 |
| 52 Week High | $6.60 | $134.65 |
Technical Indicators
Market Signals| Indicator | ACRS | ESQ |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 37.21 |
| Support Level | $5.64 | $103.79 |
| Resistance Level | $6.52 | $118.48 |
| Average True Range (ATR) | 0.29 | 3.65 |
| MACD | -0.01 | -1.90 |
| Stochastic Oscillator | 52.61 | 13.45 |
Price Performance
Historical ComparisonAbout ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
About ESQ Esquire Financial Holdings Inc.
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.